Gene therapy is entering a defining new chapter. After a period of challenge and recalibration, the field is regaining momentum, driven by resilient teams who remain committed to transforming patients’ lives. With renewed confidence, fresh investment, and major acquisitions signalling a return to growth, the industry is refocusing on overcoming the critical barriers of safety, efficacy, scalability, and commercial viability.
Designed to span the full end-to-end development pipeline, the summit connects professionals across pre-clinical development, manufacturing, analytical development, clinical operations, and regulatory affairs. Across 3 days of cutting-edge strategic and technical sessions, attendees will gain practical learnings on next-generation delivery technologies, gene editing, assay development, and scalable manufacturing strategies, all with a focus on optimising clinical impact and improving risk–benefit profiles.
Networking sits at the heart of the summit experience. With 10+ dedicated networking breaks, a CEO & Investor Panel, and carefully curated opportunities to meet peers, partners, and decision-makers, the event is built to foster meaningful, long-term industry connections. Whether you are looking to exchange technical insights, explore collaboration opportunities, or build strategic partnerships, this is the place to connect with the people shaping the future of gene therapy.
Featuring 70+ world-leading speakers, including C-level executives, scientific innovators, and regulatory leaders, the summit offers a truly comprehensive and collaborative environment for learning, discussion, and deal-making. From early-stage development through to clinical and commercial success, this is your definitive forum to stay ahead in an evolving gene therapy landscape.
To learn more about the event, visit our website here: https://ter.li/b0hfxq